An Exploratory Fixed Dose Randomized Double Blind Parallel-Group Placebo-Controlled Study of the Safety and of the Therapeutic Effects of Ro 4917523 in Patients With Treatment- Resistant Depression.
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Basimglurant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Roche
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2011 Planned End Date changed from 1 Jun 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 04 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.